ErVimmune
France
About ErVimmune
Biotechnology company developing next-generation therapeutic vaccines and cell therapies targeting 'cold tumors' using human endogenous retroviruses (HERVs) as tumor antigens, with lead candidate ErVac01 for triple-negative breast cancer and ovarian cancer.
Latest Funding
Series AAnnounced 2026-01-21
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
2 signals · where the capital is going
Driving clinical development of next-generation anti-tumor vaccines targeting hard-to-treat cancers
eu-startups.com
+1 more capital deployment signal · confidence ratings · source articles
Sign up freeIn the news
Selling to ErVimmune? You're in the right place.
Knowing they raised is the start. The edge is what's attached to ErVimmune.
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card required.
Ask AI
What is the unique value proposition of ErVimmune, and who are their main competitors?
Sign up free to ask AI about ErVimmune
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
SPRIM Global Investments
Lead investor · Series A
Tech Stack
jQuery
Complianz
Easy Pie Chart
Key Highlights
AI Insights€17M Series A first closing to fund first-in-human clinical trial of lead candidate ErVac01, an off-the-shelf cancer vaccine targeting HERV-derived epitopes for cold tumors
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to ErVimmune
Selling to ErVimmune? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to ErVimmune.
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card required.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.